YESCARTA is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Kite Pharma, Inc.. The primary component is Axicabtagene Ciloleucel.
Product ID | 71287-119_17f11ba2-5241-4e01-af69-6b4ea9ba4234 |
NDC | 71287-119 |
Product Type | Cellular Therapy |
Proprietary Name | YESCARTA |
Generic Name | Axicabtagene Ciloleucel |
Dosage Form | Suspension |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-10-18 |
Marketing Category | BLA / BLA |
Application Number | BLA125643 |
Labeler Name | Kite Pharma, Inc. |
Substance Name | AXICABTAGENE CILOLEUCEL |
Active Ingredient Strength | 2000000 1/68mL |
Pharm Classes | CD19-directed Chimeric Antigen Receptor [EPC],Genetically-modified Autologous T Cells [EPC],CD19 Receptor Interactions [MoA],T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2017-10-18 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125643 |
Product Type | CELLULAR THERAPY |
Billing Unit | EA |
Marketing Start Date | 2017-10-18 |
Marketing Category | BLA |
Application Number | BLA125643 |
Product Type | CELLULAR THERAPY |
Billing Unit | EA |
Marketing Start Date | 2017-10-18 |
Ingredient | Strength |
---|---|
AXICABTAGENE CILOLEUCEL | 2000000 1/68mL |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
YESCARTA 88466399 not registered Live/Pending |
Kite Pharma, Inc. 2019-06-10 |
YESCARTA 88351140 not registered Live/Pending |
Kite Pharma, Inc. 2019-03-21 |
YESCARTA 87067875 5402449 Live/Registered |
Kite Pharma, Inc. 2016-06-10 |